Blepharoptosis

2
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

S
SantenCA - Emeryville
2 programs
1
1
STN1013800 ophthalmic solutionPhase 31 trial
STN1013800 ophthalmic solutionPhase 11 trial
Active Trials
NCT06911216Completed8Est. Apr 2025
NCT06683651Recruiting180Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2024
2025
2026
SantenSTN1013800 ophthalmic solution
SantenSTN1013800 ophthalmic solution

Clinical Trials (2)

Total enrollment: 188 patients across 2 trials

NCT06683651SantenSTN1013800 ophthalmic solution

A Study in Chinese Patients With Acquired Blepharoptosis

Start: Oct 2024Est. completion: Jun 2026180 patients
Phase 3Recruiting
NCT06911216SantenSTN1013800 ophthalmic solution

A Pharmacokinetics (PK) Study in Healthy Adults

Start: Mar 2025Est. completion: Apr 20258 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 188 patients
1 companies competing in this space